Mounjaro is a dual-agonist medication (GLP-1 + GIP) that can deliver substantial weight loss under medical supervision.
How Mounjaro works
Tirzepatide activates GLP-1 and GIP receptors to improve satiety, reduce appetite, and support metabolic control.
Results and expectations
Clinical trials show significant weight loss when combined with lifestyle changes. Results vary by dose and adherence.
Access in Sweden
Mounjaro requires a prescription and medical assessment to ensure safety and appropriate dosing.